Comments*

 
  • Events 

    Thursday, June 11, 2015 | 8:30 AM - 4:30 PM

    Learning from Cancer to Advance Neurodegeneration Drug Discovery and Development

    Keynote Speaker: Jane Driver (Brigham and Women's Hospital)
    Speakers: Kurt Brunden (University of Pennsylvania), Gary Landreth (ReXceptor), David M. Roy (Memorial Sloan Kettering Cancer Center), Li Huei Tsai (Massachusetts Institute of Technology), Raymond Scott Turner (Georgetown University), Hui Zheng (Baylor College of Medicine), Claes Wahlestedt (University of Miami, Miller School of Medicine), Carlos Buesa, PhD (Oryzon)

    Does having cancer decrease your risk of developing neurodegenerative diseases? Why do many cancer drug targets overlap with targets for neurodegenerative diseases? This meeting will address these questions to help advance therapeutic development.

    June 15 - 17, 2015

    9th Annual Countermeasures Against Chemical Threats (CounterACT) Network Research Symposium

    Chemists, toxicologists, drug developers, pharmacists, clinicians, and public health researchers will convene to explore research aimed at improving therapeutic countermeasures and diagnostic technologies against chemical threat agents.

    October 18 - 22, 2015

    Tenth Cooley's Anemia Symposium

    Global experts explore the biology of globin gene regulation and fetal hemoglobin induction; stem cell transplant, gene therapy strategies, and gene editing; and clinical issues in thalassemia treatment and imaging.

  • Past Events

    Tuesday, February 24, 2015 | 8:30 AM - 4:30 PM

    Harnessing the Potential of Genome Editing for Drug Discovery: Translational Frontiers of in vitro and in vivo Applications

    Speakers: Chad Cowan (Harvard University), James Inglese (National Center for Advancing Translational Sciences, NIH), J. Keith Joung (Massachusetts General Hospital), Randall Platt (Massachusetts Institute of Technology), Yi Yang (Novartis Institutes for Biomedical Research), Lei (Stanley) Qi (University of California San Francisco)

    The emergence of genome editing technologies such as TALEN and CRISPR/Cas9 are revolutionizing our ability to rapidly engineer mammalian systems. This symposium explores the frontiers of genome editing and potential to aid therapeutic development.

    Thursday, October 24, 2013 | 8:30 AM - 7:00 PM

    Seventh Annual Parkinson's Disease Therapeutics Conference

    Speakers: Charles H. Adler (Mayo Clinic Arizona / Arizona Parkinson's Disease Consortium), Raymond Bartus (RTBioconsultants, Inc.), Donald E. Frail (AstraZeneca PLC), Reina Fuji, VMD (Genentech Inc.), Kimberley S. Gannon (NeuroPhage Pharmaceuticals, Inc.), Kenneth Marek (Institute for Neurodegenerative Disorders), Mary Maral Mouradian (Rutgers - Robert Wood Johnson Medical School), Adrian Newman-Tancredi (Neurolixis, Inc.), Michael A. Schwarzschild (Massachusetts General Hospital), Eric Siemers (Eli Lilly and Company), Peggy Taylor (Covance Inc.)

    Explore emerging basic and translational research that impacts our understanding of Parkinson's Disease and its treatment.

    Monday, June 24, 2013 | 10:30 AM - 3:00 PM

    Translating Immunology Discoveries into Therapies: Inaugural Ross Prize in Molecular Medicine

    Speakers: Yasmine Belkaid (National Institute of Allergy and Infectious Diseases, NIH), Dan R. Littman (New York University School of Medicine), Alexander Rudensky (Memorial Sloan-Kettering Cancer Center)

    The Ross Prize, established in conjunction with the Feinstein Institute for Medical Research and Molecular Medicine, is awarded to an investigator producing innovative, paradigm-shifting research worthy of significant attention in molecular medicine.

    Tuesday, March 12, 2013 | 8:30 AM - 4:30 PM

    The Good Fat: Understanding Adipogenesis and Function of Brown Fat

    Speakers: Sheng Bi (Johns Hopkins University School of Medicine), Sheila Collins (Sanford-Burnham Medical Research Institute, Diabetes and Obesity Research Center), Abdul G. Dulloo (University of Fribourg), Vicente Gilsanz (Children's Hospital Los Angeles), Andrew C. Larner (Virginia Commonwealth University), David A. Price, Pfizer, Inc, Devanjan Sikder (Sanford-Burnham Medical Research Institute, Diabetes and Obesity Research Center), J. Enrique Silva (Tufts University School of Medicine), Bruce M Spiegelman (Dana-Farber Cancer Institute, Harvard Medical School), Anne-Ulrike Trendelenburg (Novartis Institutes for BioMedical Research, Yu-Hua Tseng (Joslin Diabetes Center, Harvard Medical School), Richard L. Veech (National Institute on Alcohol Abuse and Alcoholism/NIH)

    This conference will present recent research exploring adipogenesis focusing on brown adipose tissue, and will explore its implications in diet-induced obesity.

  • Publications 

    Annals

    MARROW

    Edited by Mone Zaidi (Mount Sinai School of Medicine, New York, New York)

    A new series in Annals, MARROW presents cutting-edge manuscripts on basic, translational, and clinical bone and bone marrow biology and medicine.

    Annals

    Annals Reports

    Edited by Annals of the New York Academy of Sciences editorial staff

    This Annals volume presents two meeting reports: (1) Influencing circadian and sleep–wake regulation for prevention and intervention in mood and anxiety disorders: what makes a good homeostat?; and (2) One Medicine One Science: a framework for exploring challenges at the intersection of animals, humans, and the environment.

    Volume 1334

    Annals

    The 12th OESO World Conference: Cancers of the Esophagus

    Edited by Robert Giuli (Deputy Director of OESO, Executive Director of the OESO Foundation, Paris, France) and Asad Umar (National Cancer Institute, Rockville, Maryland)

    This Annals volume presents a compilation of expert views on topics related to esophageal cancers presented at the World Organization for Specialized Studies on Diseases of the Esophagus 12th World Conference.

    Volume 1325

    Annals

    The Year in Diabetes and Obesity

    Edited by Rexford S. Ahima (University of Pennsylvania, Philadelphia, Pennsylvania) and Alvin C. Powers (Vanderbilt University, Nashville, Tennessee)

    This Annals volume presents scholarly reviews by leading experts in diabetes and obesity research.

  • Webinar Archives

    Webinar Archive
    October 27, 2009

    Is Alzheimer's Disease Type 3 Diabetes?

    What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.

  • Translational Medicine Initiative

    Macy FoundationThe Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.

    Learn more at www.nyas.org/TransMed.